Cutera (NASDAQ:CUTR) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Cutera (NASDAQ:CUTR) in a report issued on Friday. The firm set a “sell” rating on the medical device company’s stock.

Cutera Stock Down 4.3 %

Shares of Cutera stock opened at $0.35 on Friday. The firm has a market cap of $7.07 million, a PE ratio of -0.05 and a beta of 1.26. Cutera has a 52 week low of $0.28 and a 52 week high of $4.97. The business’s fifty day simple moving average is $0.48 and its 200-day simple moving average is $0.93.

Institutional Investors Weigh In On Cutera

A number of institutional investors have recently made changes to their positions in the stock. Ground Swell Capital LLC acquired a new position in shares of Cutera in the 2nd quarter worth approximately $37,000. Bank of Montreal Can raised its position in Cutera by 14.2% in the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after purchasing an additional 35,248 shares during the period. Finally, Squarepoint Ops LLC lifted its stake in Cutera by 164.5% during the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock worth $172,000 after purchasing an additional 70,870 shares in the last quarter. 90.70% of the stock is currently owned by institutional investors and hedge funds.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.